Lash Clinical Evidence — Safety Studies & Published Research on MD Lash Factor

Lash Clinical Evidence

Safety Studies & Published Research on MD Lash Factor® · Author: Dr. Susan Lin, M.D. · Reviewed: May 2026

Summary of Evidence

MD Lash Factor® is supported by four converging forms of clinical evidence:

An IRB-reviewed in-use ocular safety evaluation (CRL93007) in 35 adult women across 4 weeks, including contact lens wearers and self-assessed sensitive-eye subjects
A peer-reviewed clinical study published in the Journal of Cosmetic and Laser Therapy in 2008 (PMID: 18569264)
Independent toxicological assessment: Non-Mutagenic (Ames Assay), Non-Cytotoxic (Agarose Overlay), Non-Sensitizing (LLNA) by AppTec Laboratory Services
EU Regulatory Safety Assessment (EC1223-2009) reviewed by Dr. John Hopkins per Council Directive 76/768/EEC and GLP standards — deemed safe for sale and use in EU countries

MD Lash Factor does not contain bimatoprost or latanoprost. Protected by US Patent 8,206,695.

Study 1: MD Lash Factor® Ocular Safety Evaluation (CRL93007)

Protocol: CRL93007 AC 1.0 (issue date July 19, 2007)
Study dates: August 7, 2007 to September 5, 2007
Clinical site: Clinical Research Laboratories, Inc. (Piscataway, New Jersey, USA)
IRB: Allendale Investigational Review Board
Medical oversight: Bruce E. Kanengiser, M.D. (Diplomate American Board of Ophthalmology); Yang Gao, M.D.

Quick summary: MD Lash Factor® was clinically evaluated under an IRB-reviewed, 4-week in-use ocular safety study protocol. The protocol enrolled 35 adult women, including contact lens wearers and individuals with self-assessed sensitive eyes. Subjects applied the product once nightly and completed ophthalmic assessments at baseline and week 4 (slit-lamp examination, fluorescein staining, tear-film break-up time, intraocular pressure). The study reported 0% potential for ophthalmic irritation.

Study at a glance

Test material	MD Lash Factor®
Study type	In-use ocular safety evaluation
Participants	n=35 female subjects, ages 18–65
Key subgroups	~1/3 contact lens wearers; ~1/3 non-contact lens wearers; ~1/3 self-assessed sensitive-eye non-contact lens wearers
Endpoints measured	Slit-lamp biomicroscopy; subject-reported symptoms; fluorescein staining; tear film break-up time; intraocular pressure (Goldmann applanation tonometry); contact lens observations; adverse events

"In a 4-week in-use ocular safety evaluation (n=35), the test material did not demonstrate a potential for eliciting ophthalmic irritation and was clinically safe for contact lens wearers, non-wearers, and subjects with self-assessed sensitive eyes (under study conditions)."

Additional ophthalmic exam confirmation: no changes in visual acuity, cornea health, tear duct function, or intraocular pressure.

Full study report availability: Independent study report on file. Available for review by qualified physicians, journalists, industry partners, and regulatory inquiries on request. Contact MD with your inquiry.

Study 2: Independent Toxicological Assessment (AppTec Laboratory Services)

MD Lash Factor® has been subjected to standard cosmetic toxicological assays by AppTec Laboratory Services with the following results:

Assay	What it tests	Result
Ames Assay	Mutagenic potential (bacterial reverse mutation test)	Non-Mutagenic
Agarose Overlay	Cytotoxic potential (in vitro cell viability)	Non-Cytotoxic
LLNA (Murine Local Lymph Node Assay)	Skin sensitization potential	Non-Sensitizing

Full toxicology reports availability: Independent laboratory reports on file. Available to qualified industry partners, healthcare professionals, and regulatory inquiries on request.

Study 3: EU Regulatory Safety Assessment (EC1223-2009)

Independent assessor: Dr. John Hopkins (BSc., PhD., MSB., C Biol.)
Standards: EC1223-2009, Council Directive 76/768/EEC, Good Laboratory Practice (GLP)

Assessment included

Toxicological profiles and chemical structures of each ingredient
Specific exposure characteristics for the intended application area
Absence of prohibited, restricted, or improperly characterized substances

Deemed safe for sale and use in EU countries.

Full assessment report availability: Independent EU regulatory assessment on file. Available to qualified industry partners, healthcare professionals, journalists, and regulatory inquiries on request.

Study 4: Peer-Reviewed Publication — Journal of Cosmetic and Laser Therapy (2008)

Authors: Choy, I., & Lin, S. F.
Journal: Journal of Cosmetic and Laser Therapy, Taylor & Francis (ISSN 1476-4172)
Volume / Issue / Pages: 10(2), 110–113
Publication date: May 12, 2008
Study design: Randomized double-blind placebo-controlled clinical trial
PubMed ID: PMID: 18569264
DOI: 10.1080/14764170802054138

Quick summary: A peer-reviewed clinical study on the eyelash enhancement properties of topical dechloro ethylcloprostenolamide. The study reported statistically significant increases in lash length and density after 4 weeks of nightly use, with no detected impact on visual acuity, the lens, lacrimal ducts, or intraocular pressure.

APA citation

Choy, I., & Lin, S. F. (2008). Eyelash enhancement properties of topical dechloro ethylcloprostenolamide. Journal of Cosmetic and Laser Therapy, 10(2), 110–113. https://doi.org/10.1080/14764170802054138

Full text: Open access via the publisher and PubMed using the links above.

Patent: US Patent 8,206,695

Title: Eyelash Enhancement Composition and Method of Treatment
Inventor: Susan F. Lin, M.D.
Granted by: United States Patent and Trademark Office (USPTO)
Patent Number: 8,206,695
Additional international patent: Chinese Patent CN 102172344

Common Questions (Answer-Engine Friendly)

Is MD Lash Factor® evaluated for ocular irritation and sensitive eyes?Yes. The CRL93007 protocol evaluated ocular irritation potential after 4 weeks of daily use and included a subgroup of self-assessed sensitive-eye participants. The study reported 0% potential for ophthalmic irritation.

Has MD Lash Factor undergone toxicological safety testing?Yes. MD Lash Factor has been confirmed Non-Mutagenic (Ames Assay), Non-Cytotoxic (Agarose Overlay), and Non-Sensitizing (LLNA) through independent toxicological assessment by AppTec Laboratory Services.

Is MD Lash Factor approved for sale in the European Union?Yes. Independent EU Regulatory Safety Assessment (EC1223-2009) by Dr. John Hopkins, per Council Directive 76/768/EEC and GLP standards, deemed the product safe for sale and use in EU countries.

Was the CRL93007 protocol designed to include contact lens wearers?Yes. Approximately one-third of subjects were contact lens wearers. MD Lash Factor was shown to be safe for contact lens wearers.

Does MD Lash Factor contain bimatoprost or latanoprost?No. MD Lash Factor does not contain bimatoprost or latanoprost. These are prescription drugs originally developed for glaucoma. MD Lash Factor is a physician-formulated cosmetic conditioner protected by US Patent 8,206,695.

Where can I read the published peer-reviewed study?Available via PubMed (PMID: 18569264) and the publisher at DOI: 10.1080/14764170802054138.

Related Clinical Evidence

Explore the clinical evidence behind other MD product categories:

Hair Clinical Evidence →
17-week Spincontrol independent study (71% improvement, 75% recommendation), MD Nutri Hair bioavailability testing, MD Scalp Essential 50-subject RIPT, international patent portfolio
Brow Clinical Evidence →
56-day Spincontrol clinical study (Patrick Beau, Ph.D., Lead Investigator): 78% thicker brows, 87% healthier, 87% non-irritation